Bonothyrk (20mg)
Parathyroid-Targeted Khavinson Bioregulator
Bonothyrk is listed for catalog specifications. Catalog vial contents are 20mg; select the required strength before ordering. This material is supplied for Research Use Only, not as a medicine or a product for human or veterinary use.
Research Applications & Benefits
- Parathyroid-tissue-targeted bioregulator
- Short-peptide gene-expression modulator
- Calcium-homeostasis research tool
- Khavinson bioregulator series compound
What is Bonothyrk?
A short-peptide bioregulator from the Khavinson series, sourced and studied for parathyroid-tissue-specific gene-expression modulation in calcium-homeostasis research.
Listed vial contents: 20mg. These are supplied quantities, not administration doses. Current pricing and availability are shown in the strength selector.
What mechanisms are being studied?
Bonothyrk is a short-peptide bioregulator from the Khavinson series, developed at the St. Petersburg Institute of Bioregulation and Gerontology. Like other bioregulators in this class, it is hypothesized to bind specific DNA promoter sequences in parathyroid tissue, modulating expression of genes involved in parathyroid hormone (PTH) synthesis and calcium-homeostasis signaling. Khavinson-class peptides are characterized by very short sequences (2–4 amino acids), tissue-specific activity, and low effective doses.
What are the research questions?
- Calcium-homeostasis research: Used in animal models of age-related parathyroid dysfunction to study PTH secretion and serum calcium regulation.
- Bone-metabolism research: Investigated as part of bone-health bioregulator stacks alongside cartilage-targeted (Cartalax) and bone-targeted (Sigumir) peptides.
- Bioregulator-pathway research: Provides a parathyroid-specific tool in studies comparing tissue-selective gene-expression modulation across the Khavinson series.
- Geriatric-endocrinology models: Used in preclinical models examining age-related decline in parathyroid responsiveness.
What does the published work describe?
Khavinson VKh et al. (Bull Exp Biol Med, various 2003–2018) — series of publications documenting tissue-specific gene-expression and functional effects of Khavinson short-peptide bioregulators in animal models. Published data on Bonothyrk specifically is limited and primarily Russian-language; mechanism is inferred from the broader bioregulator literature.
What are the limits of this evidence?
The research described concerns the cited experimental materials and models, not proof that this supplied vial is a treatment. Cell or animal findings do not establish human benefits. Clinical findings, where cited, apply to the tested formulation and population; they do not validate this research product for human use.
Study references
- Khavinson VKh. Bull Exp Biol Med 2003 — peptide bioregulators
- Khavinson VKh, Malinin VV. Gerontological Aspects of Genome Peptide Regulation, 2005
- Anisimov VN, Khavinson VKh. Biogerontology 2010
These are the catalog's existing bibliographic references. No new source verification is implied by this presentation.
How should I check lot documentation?
Match the product, strength and lot to an original analysis document. Literature describes experimental findings; it does not verify the contents of this inventory. A report is evidence only for the product, strength and lot it names.
How is Bonothyrk handled in the lab?
For Bonothyrk, record the product code BONO-20, selected strength and lot before opening. Follow the material-specific safety data sheet and laboratory SOP, with appropriate gloves, eye protection and containment. For a documented dry preparation, let the sealed vial equilibrate before opening to reduce condensation; minimize time open and use clean, compatible vessels.
Choose a solvent for Bonothyrk from the documented sequence or chemical identity, salt form and assay requirements. Test a small portion first and record pH, solvent composition and clarity. Do not assume one diluent works for every research material; include a solvent-only control and establish compatibility before using the stock in an assay.
For Bonothyrk, calculate mass concentration as measured material mass divided by final solution volume. Calculate molarity only with a documented molecular weight for the supplied chemical form; the catalog lists ~720 g/mol as a reference, not lot confirmation. Where available, use matched-lot net content rather than treating chromatographic purity as a mass correction. Record both stock concentration and subsequent dilution factors.
Use the documented storage conditions for the supplied Bonothyrk form and lot. For a documented lyophilized preparation, keep the vial sealed and protected from moisture; for solutions, validate temperature, light exposure and holding time in the assay. Use compatible single-use aliquots when appropriate to reduce repeated freeze-thaw. No universal temperature or 28-day solution shelf life is established by the catalog name.
A Bonothyrk laboratory protocol should record identity, product code BONO-20, strength, lot, applicable analysis results, solvent and pH, stock concentration, dilution sequence, vessel type, storage history and assay endpoints. Include vehicle and reference controls, independent replicates and predefined acceptance criteria. Separate handling validation from biological interpretation; these notes do not provide administration or dosing instructions.
Research Use Only. Not for human consumption, therapeutic, veterinary or any in-vivo use.
Product Specifications
- Compound
- Bonothyrk
- CAS Number
- Molecular Weight
- ~720 g/mol
- HPLC Purity Specification
- ≥98%
- Category
- Bioregulators
- Starting Price
- $99.00 USD
- Country of Origin
- United States
- Shipping
- Cold-chain insulated packaging, fast domestic delivery
- Payment
- Card, ACH, and cryptocurrency (10% discount)
Quality & Verification
Bonothyrk has a catalog purity specification of ≥98%; this is not a measured result for every vial. Match the product, exact strength, batch and lot to its analysis record and read only the reported fields. HPLC peak-area purity, measured content and endotoxin are separate measurements. A blank field means no result is reported, not zero or passed. A purity percentage alone does not establish identity, sterility or suitability for human use.
Frequently Asked Questions
What is Bonothyrk?
Bonothyrk is listed for catalog specifications. Catalog vial contents are 20mg; select the required strength before ordering. This material is supplied for Research Use Only, not as a medicine or a product for human or veterinary use.
What strengths of Bonothyrk are available?
The catalog lists 20mg. These labels describe vial contents, not administration doses. Select the required strength for current pricing and availability; match analysis records to that exact strength and lot.
How should I interpret Bonothyrk purity results?
Bonothyrk has a catalog purity specification of ≥98%; this is not a measured result for every vial. Match the product, exact strength, batch and lot to its analysis record and read only the reported fields. HPLC peak-area purity, measured content and endotoxin are separate measurements. A blank field means no result is reported, not zero or passed. A purity percentage alone does not establish identity, sterility or suitability for human use.
How should Bonothyrk be handled in the laboratory?
For Bonothyrk, record the product code BONO-20, selected strength and lot before opening. Follow the material-specific safety data sheet and laboratory SOP, with appropriate gloves, eye protection and containment. For a documented dry preparation, let the sealed vial equilibrate before opening to reduce condensation; minimize time open and use clean, compatible vessels.
How do I choose a laboratory solvent for Bonothyrk?
Choose a solvent for Bonothyrk from the documented sequence or chemical identity, salt form and assay requirements. Test a small portion first and record pH, solvent composition and clarity. Do not assume one diluent works for every research material; include a solvent-only control and establish compatibility before using the stock in an assay.
How do I calculate a Bonothyrk stock concentration?
For Bonothyrk, calculate mass concentration as measured material mass divided by final solution volume. Calculate molarity only with a documented molecular weight for the supplied chemical form; the catalog lists ~720 g/mol as a reference, not lot confirmation. Where available, use matched-lot net content rather than treating chromatographic purity as a mass correction. Record both stock concentration and subsequent dilution factors.
How should Bonothyrk be stored after preparation?
Use the documented storage conditions for the supplied Bonothyrk form and lot. For a documented lyophilized preparation, keep the vial sealed and protected from moisture; for solutions, validate temperature, light exposure and holding time in the assay. Use compatible single-use aliquots when appropriate to reduce repeated freeze-thaw. No universal temperature or 28-day solution shelf life is established by the catalog name.
What should a Bonothyrk lab protocol document?
A Bonothyrk laboratory protocol should record identity, product code BONO-20, strength, lot, applicable analysis results, solvent and pH, stock concentration, dilution sequence, vessel type, storage history and assay endpoints. Include vehicle and reference controls, independent replicates and predefined acceptance criteria. Separate handling validation from biological interpretation; these notes do not provide administration or dosing instructions.
Does Fmoc or Boc synthesis explain this Bonothyrk product?
Fmoc and Boc are peptide protecting-group strategies, not proof of how this Bonothyrk lot was made. For sequence-defined peptides, synthesis review can examine deletion products, incomplete deprotection and modifications using the method and matching analytical evidence. A single chromatographic peak does not by itself establish sequence.
Is Bonothyrk for human use?
No. Bonothyrk is strictly Research Use Only. It is not intended for human or veterinary use, diagnosis or treatment. Laboratory handling guidance is not an administration protocol.
Research Use Only. This product is intended for licensed laboratory research and is not for human or veterinary use.
